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Transductionted viruses (rAAV) are vectors for gene delivery. rAAVs occur in several serotypes
shown to have different transduction capabilities. Capsid sequences of the serotypes are different suggesting
that differences in gene delivery are in large part due to capsid structure. Since the available serotypes are
inefﬁcient transducers of cell lines on a particle per cell basis and inefﬁciently transduce desired target cells
in vivo there have been numerous attempts to create better vectors by modifying the capsids. A question of
interest is whether natural selection has led, and whether laboratory-based selection methods will lead, to
viruses with a sharply deﬁned optimal speciﬁcity. Here we created multiple randomly recombined capsid
species using the known AAV serotype capsid sequences by STEP and shufﬂing methods. We then used
selection to identify a viral capsid better adapted to Hep G2 cells than the known serotypes. This capsid was
then tested with other cells to determine whether the selection produced a virus speciﬁcally tailored by the
selection methodology or one of wider applicability. The selected virus turned out to be surprisingly limited
by its target cell and method of selection.
© 2009 Published by Elsevier Inc.Introduction
AAVs are a set of DNA viruses with a single-stranded genome of
about 5000 nucleotides. They comprise most members of the genus
Dependovirus of the family Parvoviridae and are most likely present
in all higher organisms. Other members of the family parvoviridae
have been found in organisms as disparate as mosquitoes and shrimp.
What particularly differentiates the AAVs from the most closely
related members of this family is their inability to replicate
autonomously except for a limited replication under certain condi-
tions of stress. In order for AAV to replicate the infected cell must be
coinfected with any of several other DNA viruses, most commonly
adenovirus or herpesvirus. This inability to replicate on their own, a
lack of known pathology, and a minimal stimulation of a host immune
response directed at the viral coat protein are key features for the use
of AAV for gene delivery. An additional attractive feature of the AAVs
for gene delivery is their ability to infect many cell types.
There are presently about 10 known distinct serotypes of AAV that
infect human cells. (There are additional isolates that may in the
future be shown to be serologically distinct.) These serotypes were for
the most part isolated as contaminants of stocks of adenovirus. In
addition searches of tissue samples from humans and other higher
primates have produced many non-identical but closely related
isolates(Chen et al., 2005; Gao et al., 2003, 2004). The preferred
target cell of each particular AAV serotype is unknown.).
lsevier Inc.The parvoviruses that have been examined have been shown to
have unexpectedly high rates of nucleotide substitution, rates on a
par with the RNA viruses (Lopez-Bueno et al., 2003; Shackelton and
Holmes, 2006; Shackelton et al., 2005). These observations along
with the discovery of the extensive variance found in natural isolates
raises the question whether natural selection may be precisely
selecting AAVs to particular targets. This issue is also of a practical
importance due to efforts to retarget and to improve the transduc-
tion efﬁciency of AAV for gene therapy. However, without knowing
the preferred target cells of different serotypes it is difﬁcult to
answer this question.
Several studies have shown that the serotypes vary greatly in rates
of transduction in a way that is cell-type speciﬁc (Wu et al., 2006).
This serotype-dependent variance in AAV transduction is probably a
function of both cellular entry and of capsid-dependent post-entry
effects (Douar et al., 2001; Duan et al., 2000; Hauck et al., 2004; Wang
et al., 2007). The observations of capsid-dependent serotype differ-
ences have motivated a search for additional serotypes as well as
attempts to modify existing AAV capsids. Efforts to modify capsids to
target receptors on speciﬁc cell types have included insertion of
epitopes into regions of the capsid previously determined by random
insertion analysis to tolerate insertions without great loss of
infectivity (Girod et al., 1999; Grifman et al., 2001; Ried et al., 2002;
Shi et al., 2001; Waterkamp et al., 2006).
A substantial advancement in the search for better vectors used a
selection method with a library of mutant AAV viruses to isolate virus
able to infect a speciﬁc cell type (Michelfelder et al., 2007; Muller et
al., 2003; Perabo et al., 2003). A random short peptide library is
inserted next to a site on the capsid involved in receptor binding. The
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those viruses that are most infectious.
In theory, if, during viral production producer constructs in each
transfected cell are expressing capsid proteins from more than one
serotype then during viral assembly the complete particle should
contain capsid subunits from more than one serotype, i.e. they would
bemosaic particles (Hauck et al., 2003; Rabinowitz et al., 2004; Gigout
et al., 2005). Using this methodology Rabinowitz et al. (2004) noted
some surprising successes as for example a mixture of AAV 1 and 2
capsids transduced C2C12 cells better than either serotype alone. In
another approach taken by the same group, which they designated
“marker rescue”, a non infectious AAV2 capsid mutant could
recombine with AAV3 wt capsid sequences in a cotransfected cell to
produce a viable virus in which capsid proteins were recombinants
between AAV2 and AAV3 (Bowles et al., 2003).
PCR can be used to produce recombinants between homologous
but non-identical DNA sequences by two basic methodologies (DNA
shufﬂing and the staggered extension procedure or STEP (Crameri et
al., 1998; Stemmer, 1994a, 1994b; Zhao et al., 1998). These techniques
have becomewidely used to produce improved enzymes for industrial
use. There are also several reports in which these technologies have
been used to recombine viral capsids including those of AAV. Six
naturally occurringmurine leukemia strains have been recombined by
DNA shufﬂing to create a library of recombinant viruses (Powell et al.,
2000; Soong et al., 2000). Using this library these investigators were
able to select for viruses with increased stability during puriﬁcation in
one case and for new tropisms in a second case. With respect to AAV
one group used error prone PCR of the AAV2 capsid gene followed by
DNA shufﬂing and selection to identify recombinants that could avoid
antibody neutralization (Maheshri et al., 2006). There have been two
reports of DNA shufﬂing of capsid genes frommultiple AAV serotypes.
One group selected a chimera that could efﬁciently infect human
hepatoma cell lines in the presence of serum antibodies (Grimm et al.,
2008). The second group selected a chimera that could efﬁciently
transduce hamster melanoma CS1 cells (Li et al., 2008).
We have chosen to exploit the rich diversity of functional epitopes
present in the natural isolates by creating recombinants between the
Cap genes of eight serotypes with PCR technology employing a
combination of shufﬂing and STEPmethods. The ﬁrst goal is to create a
library of new pseudowild type viruses that are each identical to AAV2
except that they will contain chimeric Cap genes. The library we
produced is strongly biased towards AAV2. This library can be
submitted to selection for viruses that are adapted to a chosen cell
type.We used the library to select for a Cap gene that would workwell
on Hep G2 cells, a cell line targeted more efﬁciently by AAV2 than by
other serotypes. By matching the target cell and library we are driving
selection towards post-entry events. We can then ask whether this
method of creating and selecting new viruses for post-entry efﬁcacy
would produce a virus of wide applicability or one limited by cell type.
Results
Producing a plasmid library of AAV Cap sequences
rAAV chimeras were produced using two basic methodologies
(Fig. 1A). In the ﬁrst method, known as shufﬂing, the Cap genes from
different AAV serotypes were fractionated into small pieces i.e. with a
median length of several hundred base pairs; fragments were mixed
together and a primerless PCR was performed with the principle
being that overlapping regions of homology would allow gradual
extension of the fragments into full-length products (Stemmer,
1994a, 1994b) (Crameri et al., 1998). Ideally the fragments that
anneal with each other would not be from the same serotype. In this
way chimera would be formed in which cross over points would be in
regions of homology. In the second method, known as STEP, full-
length Cap genes were mixed and a PCR with primers was performed(Zhao et al., 1998). However rather than allow full-length extension,
the extension step was interrupted after a short time by denaturing
the complexes. The repeated quick rounds of annealing and extension
allow hybridization of the partly synthesized strands to substrate
molecules of different serotypes. The requirement is only that the 3′
terminal bases of a molecule be able to anneal with the hybridizing
partner, ideally for extension on a molecule of a different serotypes.
Shufﬂing and the STEP reaction were employed both on Cap genes
from 8 serotypes and on several more limited mixtures of Cap genes.
Products were pooled prior to cloning.
Final ampliﬁcation of full-length product (cap gene) with the
appropriate primers typically yielded low or undetectable amounts of
ﬁnal product. However ampliﬁcation with primers that would
produce a fragment of approximately half-length yielded abundant
product. This higher yield was observed nomatter fromwhat region of
the Cap sequence the primers were chosen. We therefore concluded
that failure to observe much product with full-length primers
reﬂected an inefﬁciency of our shufﬂing and STEP procedures. To
capture the maximum diversity created by the shufﬂing and STEP
reactions we performed two half-length ampliﬁcations. The half-
length fragments were gel recovered and combined in a PCR reaction
to allow them to extend from each other.
For a ﬁnal ampliﬁcation PCR products were ampliﬁed with primers
that were nested with respect to primer 1 and primer 4, i.e. primers 2a
and 3a. These primers hybridized to all serotypes except AAV5. The
ﬁnal PCR products had their terminal 3′ nucleotides removed by the
exonuclease activity of T4 polymerase andwere cloned into pAVCP1 as
described in M&M to create a plasmid library. In this way we could
produce a plasmid library of greater than 60,000 clones as determined
by counting bacterial colonies. Each clone should contain the
sequence for a pseudowild type virus in that it will have the sequence
of AAV2 except for the replacement of the AAV2 Cap sequence with a
chimeric Cap sequence and a two-nucleotide difference at the newly
created Avr II site.
To ensure that the above method produces constructs that can
make viable virus we used primers 2a and 3a to amplify the wild type
AAV2 Cap gene by PCR. These products were then cloned into pAVCP1
by the abovemethods to create the pOD2 library, a recreation of pAV2.
These plasmids when transfected into 293Tcells at 8 plasmids per cell,
along with helper constructs that did not possess AAV Cap sequences
(pDG (Grimm et al., 1998) with Cap deleted), were able to produce
virus only slightly less efﬁciently than pAV2. Furthermore the virus
produced from these plasmids was fully infectious (data not shown).
Fig. 1B illustrates the quality of the plasmid library. Lane 1 shows a
Bgl II digestion of the parental plasmid with a full-length wild type
AAV2 genome, lane 2 shows a Bgl II digestion of pAVCP1. Other lanes
show a Bgl II digest of several representative sub-libraries composed
of a mix of between several hundred and several thousand clones.
After Bgl II digestion that precisely excises the AAV sequences from the
vector backbone it is apparent that the full-length of the AAV sequence
has been recreated with very little of the smear that would have
indicated insertion of less than full-length Cap sequences. To assess
the diversity of the library we picked 22 random clones for
sequencing. We sequenced 40% of each clone starting at the VP1
ATG. 30% of the cloneswere chimeric within the sequenced regions i.e.
the ﬁrst 40% of the Cap gene.
Producing a viral library
A viral library was produced from these plasmids by transfecting
them into 293T cells along with helper plasmids. We performed
transfections with the chimeric library at the ratios of 1, 4, 10, and 25
plasmids per cell. It is unclear what percentage of plasmid molecules
actually enters a productive cycle of replication and viral production.
By doing the transfections at these low ratios we could ensure that in
at least one case only one or at most a few plasmids were producing
Fig. 1. The formation and quality of the chimeric AAV library. (A) Diagrams illustrating the shufﬂing and STEP procedures employed to generate the library. (B) Bgl II digest of plasmid
libraries. Each lane represents a Bgl II digest of: lane 1, pOD2, lane 2, pAVCP1, lanes 3–7, different sub-libraries composed of a mix of between several hundred and several thousand
clones. After Bgl II digestion, which precisely excises the AAV sequences from the vector backbone, (the upper band in each case, except for pAVCP1 (lane2), is a double-stranded
version of AAV and the lower band is the vector backbone) the expected size fragment of approximately 5 kb is obtained that is equivalent in length to the full-length fragment
obtained from the wtAAV sequence (i.e. lane1).
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Table 1A
Table shows numbers of cells in brightest FITC bins for several GFP containing viruses
for a sort of 20,000 cells, P1 is brightest, etc.
Cells per bin
Uninf AAV7 AAV8 AAV9 AAV2 AAV2.2A
Bin
P1 0 0 0 0 1 8
P2 0 0 0 0 4 72
P3 0 0 0 0 70 891
P4 0 3 4 4 287 1633
P5 0 50 49 30 2002 3936
P6 11 150 149 108 2672 2768
Cells were non-conﬂuent Hep G2 cells infected with the indicated viruses.
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two plasmids were simultaneously transfected into one cell there was
an unexplained mechanism coupling packaged genome to the capsid
for which it coded (Ward et al., 2007). However this mechanism may
not prevail when very large numbers of unique plasmids are
simultaneously transfected into one cell.)
It is important to produce on the initial passage through cells, i.e.
the transfection, virus particles in which the capsid is encoded by the
genome that is encapsidated. If the genomes are cross-packaged they
could in theory be sorted out by a second passage through the 293T
cells at a low MOI. However, this second passage would select for
capsids that do best on 293T cells; useful genomes packaged in
capsids that do not efﬁciently infect 293 cells might be lost. If we
depend on the ﬁrst infection of the target cells, rather than the viral
production in 293 cells, for sorting out the virus so that genomes
match capsid we risk losing good genomes because the unrelated
capsid in which they are contained may not efﬁciently infect the
target cell.
In all these transfections the amount of helper plasmid pDG
(Grimmet al., 1998) was kept constant at 140,000 plasmids per cell. As
seen in Fig. 2 even at the lowest ratios there was some viral
production. By adjusting the amount of viral genomes applied to a
gel we can determine that the amount of virus product when
transfecting 4 plasmids/cell is not less per plasmid than that produced
when transfecting 1 plasmid/cell. This implies that at these ratios
there is no interference between plasmids. By contrast when 2000
plasmids per cell are compared with 1 or 4 plasmids per cell it is clear
that the lower plasmid number transfections are producingmore than
10× as much virus per plasmid molecule as indicated by the intensity
of staining once the amount of product loaded in each lane is
accounted for. It is also clear that the amount of virus produced per
plasmid from the chimeric library is much less than that produced
from pAV2 or OD2 implying that many of the recombinants do not
produce viable virus. The fact that OD2 produces virtually the same
amount of virus as pAV2 demonstrates that the cloning methodworks
well. Therefore the lower amount of virus from the chimeric library
may be due to many of the chimeric capsids having a structure
incompatible with a viable virus particle or with efﬁcient virus
production.Fig. 2. Chimeric virus made from the chimeric plasmid library. Shown in each lane in
the upper row is the number of plasmids transfected per cell; in the lower row is the
relative amount of material loaded in each lane. The slower migrating material in each
lane is the helper plasmid pDG. The line indicates the position of single-stranded (ss)
AAV genomes packaged in viral particles. On the right is a BglII digest of pAV2 boiled
prior to loading on the gel. The most intensely staining lane represent full-length ss
AAV genomes.There were several additional considerations in viral production
from the plasmid library. The ﬁrst is time from transfection to
harvesting. Typically cells are harvested approximately 48 h post
transfection. This time point has been chosen as optimal for AAV2
production in 293T cells. At this point viral production is substantial
but virus is largely still within the cells. Those viruses that have been
released from the cell have most likely not had time to complete a
second round of infection and viral production. (We have observed
that as much as 50% of wt AAV2 virus is present in the media at 48 h,
Ward et al., unpublished.) It is useful to interrupt the viral replication
cycle before a second round of infection because a second round of
infection would bias the library towards capsids that can infect 293T
cells, i.e. the producer cell, most efﬁciently. However 48 h might be
insufﬁcient to package some chimeric constructs that could con-
ceivably negotiate the steps to completed particle; i.e. capsid
assembly, packaging, and capsid maturation more slowly than wild
type AAV2. Consequently in several viral preparations harvesting was
delayed till 72 h post transfection. A worry is that this virus would
quantitatively represent mostly species that had completed a second
round of replication. If a second round of replication had been
completed in many cells then viral production for these delayed
harvests should have reached much higher levels. This was not the
case suggesting that the 72 h time point is still early enough to
preclude extensive second round replication. To ensure that the virus
being produced from the plasmid library was infectious a sample of
virus produced from the transfected library, at 4 plasmids per cell, was
used to infect 293T cells.
To evaluate the viral library, particles were recovered from cells.
After benzonase/DNAse digestion viral genomes were isolated by
phenol/chloroform extraction followed by precipitation. After sub-
sequent resuspension a PCR was performed using primers to amplify
the entire Cap genes. (These primers would hybridize to all
serotypes except AAV5.) The resulting full-length Cap genes were
cloned into pBluescript vectors and sequenced. Unexpectedly when
clones were selected from the total original viral library it was
determined that the total library was mostly wild type AAV2. Out of
20 randomly chosen clones all 20 were AAV2. (The total viral library
was a collection of many smaller viral libraries, some of which, when
sequenced, were found to contain chimeric clones.) Since the
original plasmid library contained many wild type sequences other
than AAV2 (in particular it apparently contained many clones of wild
type AAV8, data not shown) the potential inability of chimeric clones
to make viable virus after transfecting 293T cells cannot explain the
overwhelming percentage of AAV2. Subsequent experimentsTable 1B
Mean FITC value for all cells infected with the indicated viral serotype
Cells per bin
Uninf AAV7 AAV8 AAV9 AAV2 AAV2.2A
FITC mean
Values 14 30 32 28 496 2073
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recombination between the helper plasmid pDG that contained an
intact Cap gene and the plasmid library in the 293T producer cells
(data not shown). We had found that in normal transfections
recombination between pDG and the replicating construct was very
low. However in those assays the ratios of the two plasmids was 1:1
while in these transfections the ratio had been 140,000 pDG
plasmids per cell to 1–25 chimeric plasmids per cell. The presence
of AAV2 capsids in each cell should result in some copies of each
chimeric genome being packaged into AAV2 capsids. This would
allow the viral library to be ampliﬁed by using it to reinfect
293T cells which are readily infectable by AAV2 but not by most
of the other serotypes nor presumably by most of the chimeric
capsids.
Selection on cultured cells
This viral library with a low ratio of chimera to wt AAV2 was useful
to determine whether selection could favor uncommon clones. It is
important to note that the point of our selection was to derive vectors
that were more efﬁcient on the chosen cell type not vectors that were
retargeted. To that end we chose the cell lines Hep G2 and Hep 3B for
which AAV2, the main component of our library, was an efﬁcient
transducing agent. (We performed comparative transduction assays
on Hep G2 cells and Hep3B cells by infecting themwith AAV serotype
vectors 1–9, all containing the same GFP construct. AAV2 gave the
highest percentage of positive cells for both cell lines. Data not
shown.) Non-conﬂuent cultures of Hep G2 and Hep 3B cells were
infected in parallel with the viral library at several dilutions followed
4 h later by adenovirus infection. AAV was harvested two to 3 days
post-infection. The virus harvested from the ﬁrst passage was
subsequently used at several dilutions to infect another culture of
the same cells. This was repeated in parallel in each cell line through
three serial passages. In each case infections were performed with
virus from the dilution that produced the lowest detectable amount of
virus in the previous infection. After the third passage virus was
recovered and viral DNAwas extracted. Cap sequences were ampliﬁed
by PCR then cloned into a blue script vector. Random clones were
sequenced.
Despite AAV2 being the best serotype vector on these cells and
despite the starting viral library being overwhelmingly AAV2, 3 serialFig. 3. Diagram of the VP1/VP2 unique portion of the Cap gene of AAV. The diagrams represen
number on the left is the number of sequenced clones with the structure shown. Clones with
AAV2.2A. Designations for AAV2, AAV7, and AAV8 are at bottom.passages in both the Hep G2 and the Hep 3B cells yielded chimeric
virus. In the case of Hep G2, 12 out of 47 sequenced clones were
chimera. In the case of Hep 3B, 9 out of 40 sequenced clones were
chimera. All sequenced viruses that were not chimeric were wild type
AAV2. The appearance of chimera indicated that chimeric sequences
could produce viable viruses in this system. The increase in the ratio of
chimeric viruses to the total viral population after passage through
either of the 2 cell lines indicates that certain chimera were at some
replicative advantage in these cells compared to wild type AAV2.
None of the Hep 3B clones (which were predominantly of one
structure) were the same as any of the Hep G2 clones. Of the 12
chimeric Hep G2 clones, 3 were identical to each other and 9 were
unique. However of these 9 clones, 5 had structures that were quite
similar to the three that were identical while one other had a structure
that was somewhat similar.
Nine of the 12 Hep G2 clones had an AAV7/AAV2 junction in
approximately the same region of the VP1/VP2 unique region of the
Cap gene. Fig. 3 illustrates the VP1/VP2 unique region of AAV,
where the recombinations that formed these 9 clones occurred. 8 of
these junctions occurred between bases 2716–2720 (AAV2 number-
ing) and one junction at a somewhat close site, between bases 2629–
2633 (AAV2 numbering). The three identical chimeras were entirely
AAV7 from the ATG of VP1 until the transition to AAV2. The other 5
clones had varying amounts of AAV8 or AAV2 or both before
transitioning to AAV7. In addition 7 of the 8 sequences with the
2716–2720 AAV7–AAV2 junction as well as the one sequence with the
2629–2633 junction also contained a one base mutation in the AAV2
sequences of the VP3 region at AAV2 base 2877. The original AAV2
nucleotide, “G” has been replaced by “A”, which is the base found at
this position in AAV7 as well as in AAV 3 and 6. (We found only one
virally derived clone with an “A” in this position in the many
sequenced clones that were AAV2 derived in this region but which did
not contain the AAV7 component in the VP1/VP2 region.) Interest-
ingly this base is one of the few bases in which the two original
sequences of AAV differed (Rufﬁng et al., 1994; Srivastava et al., 1983).
The 1983 group, sequencing a viral isolate, found a “C” in this position
while the other group, sequencing cloned AAV, found a “G”. The clone
we used to make our chimera had a “G”. The substitution of an “A” for
a “G” in this position is silent and so the reason for its presence is
unclear. None of the Hep 3B selected clones were the same as any of
the Hep G2 selected clones. The “A” at 2877 was also not found in thet the structures of the 9 similar Cap genes from the viruses selected on Hep G2 cells. The
an “A” at base 2877 are designated by an “A” on the right margin. The asterisk denotes
Fig. 4. Capsid-protected DNA from viral preparations. Chimeric rAAV were produced
using co-transfections of pTRUF11, pXX6, and the AAV helper vector with the indicated
Cap gene. Shown are AAV2, AAV7, AAV8, AAV9, AAV2.2A, AAV2.2B, and AAV2.2C and a
control lane. The AAV2.2B helper failed to make a virus. Products were extracted as
described in M&M then electrophoresed on an 0.8% agarose-TBE gel that was
subsequently stained with SYBR Gold.
Fig. 5. (A) Photomicrograph under UV light of conﬂuent Hep G2 cells, showing cells positive
dot plots of FITC vs. SSC. Vertical lines designate FITC bins. A. is a plot from uninfected Hep G
cells. 20,000 cells were analyzed in each case. Bins are indicated.
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seen after selection were among the 9 chimeric clones sequenced
from the plasmid library.)
Transduction of Hep G2 cells
The selection method had been based solely on efﬁcient viral
replication. Because there are functions common to transduction and
replicationwe examined a representative chimeric clone for its ability
to transduce Hep G2 cells in comparison to AAV2. We excised one
chimeric Cap sequence from the pBluescript derived sequencing vector
and inserted it into a packaging construct as described in M&M. We
called this vector p2.2A. We used packaging constructs to produce
stocks of recombinant virus with pTRUF11 (containing the GFP cDNA).
The chimeric serotype (whichwe have designated AAV2.2A andwhich
is denoted by an asterisk in Fig. 3) is an AAV8–AAV7–AAV2 chimera.
Using AAV2 numbering, the AAV8 to AAV7 transition occurs between
nucleotides 2671 and 2694 while the AAV7 to AAV2 transition occurs
between nucleotides 2716 and 2720. Fig. 4 shows a comparison by gel
electrophoresis of the encapsidated single-stranded GFP containing
genomes fromequivalent aliquots fromproduction assayswith several
serotypes. AAV2.2A packages as well as the serotypes shown do.
Non-conﬂuent (i.e. dividing) Hep G2 cells were infected with viral
stocks at 4000 genome containing particles per cell (determined by
gel electrophoresis and SYBR Gold staining as described in M and M).for GFP. Cells are AAV2-GFP, or AAV2.2A-GFP infected. B. Quantization of GFP. Shown are
2 cells. (B) is a plot from AAV2 infected Hep G2 cells. C. is a plot from AAV2.2A infected
Fig. 6. Dot plot–Threshold. Shown are dot blots of PE vs. FITC without or with infection
by a GFP expressing virus. Diagonal line designates the division between cells counted
as negative (P11) and those to the right of the diagonal, which were scored as positive.
Box P12 designates those positive cells that are in addition scored as having reached the
threshold value. Shown are dot plots from uninfected and infected cells.
Table 2
Threshold ratios
Threshold values
Ratio AAV2 to AAV2.2A AAV2 AAV2.2A
Hep G2 non-conﬂuent 1 1.41
1 1.97
1 2.14
Hep G2 conﬂuent 1 1.39
Hep B3 non-conﬂuent 1 0.75
1 0.91
1 1.06
293T non-conﬂuent 1 1.00
293T conﬂuent 1 1.09
Thresholds for time in culture experiment
Hep G2, non-conﬂuent
2 days 1 2.44
4 days 1 1.74
6 days 1 1.67
9 days 1 1.78
Table shows ratios between matched infections of AAV2 compared with AAV2.2A for
different cell types. Each number represents a separate infection. Numbers are ratios of
percent of positive cells in each infection that are at the threshold value. In each
comparison the AAV2 ratio is arbitrarily set to 1.00. All assays from this table were with
same AAV2 and AAV2.2A viral preparations.
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parallel cultures of Hep G2 cells harvested 48 h post-infection showed
that approximately as much AAV2.2A-GFP is cell-associated as AAV2-
GFP. (In this single measurement there was slightly more AAV2-GFP
than AAV2.2A-GFP. Data not shown). This procedure did not
distinguish between genomes that are internalized versus those
bound to the cell nor did it distinguish between genomes that have
been uncoated from those that have remained encapsidated.
Fig. 5A shows the transduction of Hep G2 cells (60% conﬂuent at
infection) infected with AAV2-GFP and AAV2.2A-GFP recombinant
virus 2 days prior to being photographed. Virus with AAV2 or AAV2.2A
capsids lead to substantial numbers of visibly green cells with more
visibly green cells in the case of AAV2.2A. AAV 4 capsids with GFP gave
no green cells; AAV5, 7, 8, and 9 capsids with GFP gave a low number
of green cells; AAV1, 3, and 6 capsids with GFP gave higher numbers of
green cells but at a lower level than AAV2. AAV3-GFP gave more green
cells than did AAV1-GFP or AAV6-GFP (data not shown).
Transductionwas also assessed by ﬂow cytometry. Flow cytometric
analysis (Fig. 5B) showed that the difference between the two viruses
is not as substantial as it appears in Fig. 5A. Almost as many cells are
transduced by AAV2-GFP as by AAV2.2A-GFP but most AAV2
transduced cells are not expressing sufﬁcient GFP to be detectable at
the exposure of Fig. 5A. Table 1B gives the mean FITC values of all cells
in a typical assay.
Table 1A shows a second method of analysis. The cells are divided
into bins based on intensity of the FITC signal. Each bin represents a
one-half log difference in intensity with P1 being the brightest. Table
1A shows the number of cells in the brightest FITC Bins. (Fig. 5B shows
the dot plots and Bin divisions for one control infection and an AAV2
and an AAV2.2A infection. As seen in Table 1A, the number of the
brightest cells in a typical assay is greater for AAV2.2A than for AAV2.
A third method of analysis is illustrated in Fig. 6. For untransduced
Hep G2 cells, the ratio of their natural ﬂuorescence signal falling in the
PE (phycoerythrin) and FITC channels is constant, whereas GFP
expression adds disproportionately to the signal in the FITC channel.
Thus, we can use the FITC/PE ratio to differentiate betweenuntransduced cells with an inherently high FITC signal from those
whose high FITC signal is partly due to GFP expression. When FITC is
plotted against PE the cells fall into two classes, with the GFP
expressing cells on the lower diagonal. Cells that have reached the
lower diagonal have achieved the highest ratio of FITC to PE. Any
additional GFP expression results in an increase in both FITC and PE in
proportion to the amount emitted by excitation of GFP and the cells
move up the diagonal to the right. Ameasurement of the proportion of
positive cells that lie along or close to this diagonal, whichwe term the
threshold value, is therefore a measurement of how many of the
positive cells have increased their relative FITC to PE ratio to the
maximum amount.
This method of analysis can partly compensate for widely varying
baseline FITC values of different cells prior to infection. Table 2 gives
the ratio of the percent of AAV2 and AAV2.2A transduced cells from
matched infections that have reached this threshold. As shown, in
each assay performed on non-conﬂuent Hep G2 cells a greater
percentage of the positive cells from the AAV2.2A infection have
reached this threshold in comparison to the positive cells from the
AAV2 transduction. We think this last analysis captures the advantage
of the AAV2.2A chimera. In Hep G2 cells at 2 days post-infection the
cells transduced byAAV2.2A are expressing GFP at higher levels than
the cells transduced by AAV2.
However not all parallel AAV2 and AAV2.2A preparations demon-
strated this much advantage of AAV2.2A compared with AAV2. In
some preparations AAV2.2A was only marginally better in percentage
of cells that were transduced or in the relative numbers of the
greenest cells. This most likely reﬂects two issues. First it is somewhat
difﬁcult to determine comparative viral titer to this accuracy. We
measured our virus in two ways: by gel electrophoresis of packaged
genomes as described above and by real time PCR. In each case the
results were different both in absolute titer and more importantly in
relative titer. We used the electrophoresis results to determine the
amounts of each prep to use in our assays. The electrophoretic
measurement always gave a relatively higher concentration of
AAV2.2A than AAV2 in comparison to real time PCR. By using only
the gel electrophoresis values we may have been erring on the side of
caution in using less AAV2.2A than AAV2.
In addition to the problem of absolute numbers of viral particles an
additional confounding variable is the quality of the capsid. Different
Table 3B
Shows numbers of cells in brightest FITC bins
293T cells non-conﬂuent
Uninf AAV2 AAV2.2A
Bin
P1 0 205 189
P2 1 532 476
P3 15 2701 2375
P4 171 2718 2663
Cells were HEK 293Tcells, non-conﬂuent at infection, harvested at 2 days post-infection.
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infectivity. The possible causes of this variance are numerous;
misfolded capsid, poorly assembled capsids, varying ratios or
distributions of VP1 and VP2 in the particles.
Since we are asking whether selection produces a virus narrowly
adapted to the selection conditions or a virus of more general utility it
was advantageous to compare preparations of virus in which
measuring differences was simple and so the remaining assays in
this report were performed with the preparations compared in Figs. 5
and 6. It should be mentioned that in a parallel virus preparation in
which AAV2.2Awas only marginally better than AAV2 by the ﬁrst two
criteria, AAV2.2A still retains its comparative advantage in that among
the positive cells it gives a proportionately larger number of cells with
a maximum FITC to PE ratio. Three separate assays with those stocks
gave AAV2 to AAV2.2A ratios of 1:1.26, 1:1.31, 1:1.29.
In subsequent assays we only compare the chimeric capsid with
AAV2 because: 1. AAV2 was distinctly better than the other eight
serotypes in the cell lines we dealt with (data not shown), 2. AAV2 is
in a sense the parental virus for the chimeric virus AAV2.2A, and 3. our
selection method was in essence a competition with AAV2.
Transduction of Hep 3B cells
We next wanted to know whether the advantage that AAV2.2A-
GFP demonstrated in comparison to AAV2-GFP would be maintained
in a human hepatocyte cell line other than Hep G2. We chose Hep 3B
for the comparison. As mentioned above we had performed a parallel
selection in Hep 3B cells with the same library we had used in the Hep
G2 cells. The fact that viruses closely resembling our chimeric clone
comprised 9 out of 47 sequenced clones taken from the Hep G2 cells
while it was not found in the 40 clones taken from the Hep 3B cells
suggests that the chimera may not behave in Hep 3B as it does in Hep
G2. The results of a comparative transduction assay of Hep 3B cells are
shown in Table 3A. The AAV2.2A-GFP virus was only slightly better
than AAV2-GFP in numbers of cells transfected and no better in the
number of very positive cells, or in the relative threshold values. In
three separate infections of Hep 3B cells the relative AAV2:AAV2.2A
threshold values were 1:0.75, 1:0.91, and 1:1.06 (Table 2). This failure
to detect an advantage for AAV2.2A occurred in infections of both non-
conﬂuent (i.e. dividing) and of conﬂuent cells. This result was
reinforced by two additional assays. We infected non-conﬂuent Hep
3B cells with sufﬁcient AAV.2A-GFP to give 3× asmany positive cells as
a parallel infectionwith AAV2-GFP. Nevertheless the threshold ratio of
AAV2-GFP to AAV2.2A-GFPwas 1:0.92.We also infected conﬂuent Hep
G2 cells with larger relative amounts of AAV2.2A-GFP relative to
AAV2-GFP. The threshold ratio in this assay was 1: 1.03.
We also asked whether the advantage that AAV2.2A demonstrated
in comparison to AAV2 might be maintained in a non-hepatocyte
human cell line such as HEK293T cells. (We compared serotypesTable 3A
Table shows the numbers of cells in brightest FITC bins and FITC mean and median for
positive cells
Hep 3B non-conﬂuent
Uninf AAV2 AAV2.2A
Bin
P1 0 1 4
P2 0 5 5
P3 0 31 37
P4 0 53 118
P5 0 416 727
P6 21 607 1018
% pos 0.1 17.4 28.9
FITC median 5040 5392
FITC mean 17,238 18,529
Cells were Hep 3B cells, non-conﬂuent at infection, harvested 7 days post-infection.AAV1–AAV9 in 293T cells. AAV2 was distinctly the best transducer
as measured by percentage of positive cells. Data not shown.) The
results of a typical experiment are given in Tables 3B. The percent of
transfected cells and the numbers of the greenest cells are, as with the
Hep 3B cells, essentially equivalent. In addition the threshold values,
which we think are the most relevant indicator for the relative
advantage of AAV2.2A in comparison to AAV2, are in 293T cells also
essentially equivalent (Table 2).
Conﬂuent Hep G2 cells
We had performed the original selection in Hep G2 cells that were
dividing and had harvested the cells two to three days post-infection.
We therefore asked whether the comparative transduction advantage
of AAV2.2A-GFP relative to AAV2-GFP in dividing cells would extend to
non-dividing cells and whether it would be maintained for longer
periods in culture. Table 3C demonstrates a comparative infection of
conﬂuent Hep G2 cells. Cells were harvested 6 days after infection
because GFP expression rose more slowly and remained lower than in
dividing cells. The relative threshold values for AAV2-GFP and
AAV2.2A-GFP remain different (Table 2), however, the difference is
now greatly diminished.
In infections by AAV2.2A-GFP and AAV2-GFP of dividing cells there
is a substantial difference between the two viruses when transduction
is examined 2 days post-infection. To determine whether this
difference would persist we performed two sorts of assays. In the
ﬁrst a culture of non-conﬂuent cells was infected and allowed to grow
to conﬂuence. The cultures were maintained at conﬂuence, i.e.
without passage, with frequent media changes for 12 days at which
point the cells were harvested. The possibility being tested is that
AAV2.2A capsid simply leads to faster expression of the transgene and
that with longer times transgenes delivered by AAV2 will “catch up”.
Although the difference between AAV2 and the chimera has decreased
substantially fromwhat is seen 2 days post-infection it is not the case
that they are equivalent (Table 4). To test the possibility that the
difference between the two viruses does decrease with time but
rather slowly, i.e. the 12 days of the experiment was not long enough
for the AAV2 infected cells to “catch up”, we performed a time-course
assay. In this assay 4 plates were infectedwith each virus. Pairs of plate
were harvested at 2 days, 4 days, 6 days, and 9 days. At day 2 therewasTable 3C
Hep G2 conﬂuent
Uninf AAV2 AAV2.2A
Bin
P1 0 3 12
P2 0 22 71
P3 6 288 602
P4 181 687 988
P5 1579 1763 1819
% pos 0.0 10.0 14.3
FITC median 36,547 38,824
FITC mean 57,690 64,844
Cells were Hep G2 cells infected at conﬂuence and harvested at 6 days post-infection.
Table 4
Table shows several variables for AAV2 and AAV2.2A infections of non-conﬂuent Hep G2
cells harvested after 12 days in culture
Hep G2 non-conﬂuent
12 days in culture AAV2 AAV2.2A
% positive 9.4 16.5
FITC mean 15,626 20,491
Threshold 1 1.40
FITC values
Bin
P1 10 15
P2 9 57
P3 103 288
P4 139 343
P5 304 622
P6 382 637
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(Table 2). However, the threshold value remained constant thereafter
suggesting that there is a time interval during which AAV2 partially
“catches up” but that it is relatively brief and that the difference
observed at longer times might represent a steady state.
In the second assay cultures of non-conﬂuent Hep G2 cells were
infected in parallel. When the cultures became conﬂuent they were
split 1:5. This was repeated 4 times. As expected AAV2.2A had more
cells with high GFP expression at the ﬁrst passage. Somewhat
surprisingly many cells expressed GFP through all ﬁve passages
(each involving 2–3 cell divisions) suggesting that some GFP genomes
were integrating. Whether the persistence of GFP expression is due to
the integration of viral genomes or to another mechanism, over
several passages the comparative advantage that AAV2.2A has relative
to AAV2 rapidly diminishes. By the 3rd passage, the threshold ratios
were essentially 1:1 (data not shown). If non site speciﬁc integration
of the delivered genome is the explanation for the persistence of
expression the data suggests that while AAV2.2A may transduce more
cells and may lead to higher GFP expression in these cells it is not
more likely to randomly integrate than its parental virus AAV2.
Discussion
In this report we produce viable AAV with chimeric Cap genes
using methods recently employed for recombining the Cap genes of
AAV. We selected our chimeric virus with the goal of efﬁcient
transduction of the liver-derived cell line Hep G2. Our selection
method was based on efﬁcient replication. The virus that enters the
cells, uncoats, and replicates most efﬁciently would rise to dominance
in our viral population. It was not clear that any chimeric-capsid virus
would be able to successfully compete with wild type AAV2 in this
selection on cultured human cells. Nevertheless, the presence of
AAV2.2A or clones very similar to AAV2.2A (at a ratio of 9 out of 47
clones in the virus population after three passages) while it was not
found in 22 clones sequenced before selection) suggests that this
particular class of chimeric viruses is at some advantage for rapid and
efﬁcient replication in Hep G2 cells in comparison to AAV2. We
designed our selection scheme, i.e. choosing cell lines that are
efﬁciently entered by AAV2, with the goal of identifying chimera
that would negotiate the post-entry components of the infection
pathway better than AAV2. The scheme of course selects virus that
negotiate the complete pathway, including cellular entry, with
greatest efﬁciency. That the resultant chimeras were chimeric for
only the VP1/VP2 unique regions suggests that selection was most
likely for post-entry components of the infectious pathway. (The VP1/
VP2 regions of the capsid are thought to remain sequestered within
the particle till after viral entry (Weichert et al., 1998; Cotmore et al.,
1999; Kronenberg et al., 2001, 2005).The next question is whether the capsid from this virus that had
been selected based on replication would also support better
transduction than the AAV2 capsid. There are several requirements
common to both viral replication and transduction of a transgene but
also important dissimilarities. A principle dissimilarity is the presence
of adenovirus in replication. In particular Xiao et al. (2002) have
shown that adenovirus may help the AAV genome to enter the
nucleus. A second important difference is that in replication the AAV
Rep protein plays a major role.
To test whether there might be a correlation between efﬁcient
replication and efﬁcient transduction for our selected chimera we
constructed a helper plasmid with the AAV2 Rep gene and a capsid
gene from one of the chimera. The recombinant virus did demonstrate
slightly better transduction than AAV2. The data is consistent with a
model in which this better transduction is linked to the ability of
AAV2.2A to deliver GFP genomes in such a manner that they achieve a
higher expression in the transduced cell and/or achieve it more
quickly. It is unclear why transduction is better. It has been shown by
mutational analysis that the PLA2, BC1, BC2, and BC3 domains found in
the VP1/VP2 region play a signiﬁcant role in infectivity (Sonntag et al.,
2006; Grieger et al., 2006). While the crossover point common to 8 of
the 9 selected similar clones (Fig. 3) occurs just downstream of the
BC3 domains the AAV2, AAV7, and AAV8 BC domain regions of VP1/
VP2 are highly conserved, lessening the likelihood that they are the
reason for the difference in transduction between AAV2 and AAV2.2A.
Interestingly when the more than 100 sequenced isolates of
mammalian AAVs were analyzed for natural recombinants it was
noted that of 5 likely recombinants observed three were in the VP1/
VP2 unique regions and one other was nearby (Takeuchi et al., 2008).
It may be that natural selection favors exchange in this region. It was
also noted that the basic serotypes could be divided into two clusters
with the VP1/VP2 unique regions within each cluster being more
conserved than the VP3 region. The 9 clones that we have selected
that are similar to each other have in each case basically exchanged a
VP1/VP2 region from one cluster for that of the other cluster. (AAV7
and AAV8 are in the same cluster.)
The better transduction by AAV2.2A allowed us to address, in this
limited context, the principle question. Will this virus, which has
been selected for post-entry efﬁciency, demonstrate a general
advantage or one limited by cell type, i.e. will AAV2.2A be a generally
better transducer of cultured cells than AAV2 or superior only on
Hepatoma cell lines or perhaps superior only on the Hep G2 cell line
used for its selection.
The new virus, AAV2.2A, immediately failed to show superior
transduction on additional cell lines. When we tested this chimeric
virus for its ability to transduce 293Tor Hep 3B cells it was found to be
indistinguishable from AAV2. It is important to note that both these
two additional cell lines were most efﬁciently transduced by AAV2
among the basic serotypes (data not shown). In addition when
selecting the same library on the Hep 3B cell line all the selected
chimera were also chimeric only in the VP1/VP2 unique region
demonstrating that the basic capsid shell of AAV2, found on both AAV2
and AAV2.2A, was as optimally efﬁcient for Hep 3B cells as for Hep G2
cells. This suggests that the failure of AAV2.2A to demonstrate superior
transduction in Hep 3B cells is, like its success in Hep G2 cells, a
function of post-entry processing.
Even more strikingly, when we tested the chimera on Hep G2
cells under conditions different from those used for the selection
protocol, namely on cells that were conﬂuent and therefore not
rapidly dividing, the advantage to the chimera was greatly
diminished as assessed by the number and brightness of the
transduced cells. (The threshold ratio did remain elevated 1:1.39
(Table 2) indicating the virus still retained some advantage on non-
rapidly dividing Hep G2 cells.)
This last observation suggests the possibility that a precisely
deﬁned adaptation to the circumstances of infection and replication
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the case. When Wilson and his colleagues sequenced numerous AAV
genomes from various nonhuman primates (Gao et al., 2003, 2004)
they found these genomes could be grouped into classes around the
several AAV serotypes but that almost every isolated and sequenced
genome differed slightly from every other. Johnson and Clark and
their colleagues observed a similar phenomenon when they isolated
AAV from children in one city in Ohio (Chen et al., 2005). They
characterized 8 isolates; all but one manifestly of the AAV2 lineage
though none was the paradigm AAV2. Only 2 of these 8 genomes
were identical. That these viruses differed from AAV2 substantially
more in their Cap than in their Rep genes suggests that the
differences were functional.
E. Holmes and his colleagues have shown that CPV and B19 have
high rates of nucleotide substitution (Shackelton and Holmes, 2006;
Shackelton et al., 2005). While there have been no comparable
analyses of the AAV viruses, the data from Wilson and Johnson and
their colleagues suggest that the high substitution rate in the
autonomous parvoviruses is likely also true of the AAVs. Indeed
Holmes et al. speculate this may be true of the ss DNA viruses
generally since circoviruses and Gemini viruses also have high levels
of diversity. They conclude that the single-stranded DNA viruses have
substitution rates as high as the single-stranded RNA viruses and the
most mutation prone among the retroviruses (Duffy et al., 2008).
These observations raise two questions. First, how is the high
mutation rate upon which a high substitution rate in part depends
achieved, since all the single-stranded DNA viruses are believed to use
host replication systems? The mechanism is unknown but it has been
suggested that the single-stranded nature of their genomes may alter
the ﬁdelity of the host polymerase or the efﬁciency of proofreading
and repair systems (Shackelton and Holmes, 2006; Shackelton et al.,
2005). The second question, relevant to the issue of engineering new
vectors, is why do these viruses have such a high mutation rate. A
widely accepted hypothesis in viral evolution is that viruses are
selected for a mutation rate that is commensurate with their natural
history (Drake, 1999) though counter views have been proposed
(Malpica et al., 2002). Experiments with several viruses have
demonstrated that a slight increase in mutation rate can drive a
virus into what is known as “error catastrophe” inwhich its infectivity
suffers a severe decline (Domingo, 2000). Conversely a decrease in
mutation rate renders a virus less competitive. Recently, for example,
it has been shown that in poliovirus a 6-fold increase in polymerase
ﬁdelity results in a virus that replicates as well as the wild type virus
but that is almost non-pathogenic(Vignuzzi et al., 2006, 2008).
The suggestion is that the high substitution rate is important for
the parvoviruses or a lower rate would have been selected. Their wide
range of host organisms implies that the parvoviridae have been
evolving with their hosts for a considerable time. The maintenance of
a high substitution rate despite extensive time for adaptation to the
host suggests that a rather precise matching of the virus to the speciﬁc
cell type and conditions of infection may be important for the virus to
achieve an efﬁcient infection. In this scenario the high substitution
rate reﬂects the need to search for that match in each infection. An
alternative suggested previously for the parvoviruses (Lopez-Bueno et
al., 2006) is that successful infection by AAV may be dependent upon
the extensive variance found in a quasispecies. In that scenario
efﬁcient infection is accomplished not by one optimal sequence but by
a population of sequences that complement each other.
The AAVs are considered to be viruses that can infect a wide range
of cell types, albeit very inefﬁciently with respect to the number of
genome containing particles needed to transduce one cell. However, it
may be that each known serotype can infect/transduce a particular
cell type efﬁciently. In this report, we attempted by recombining the
capsids of the known serotypes, to develop a virus better suited to a
chosen cell — here the Hep G2 cell. Hep G2 cells are more efﬁciently
transduced by AAV2 than by other serotypes. The fact that we wereable to produce a virus better adapted to that cell than AAV2 supports
the notion that AAV capsids may be adapted for improved gene
transfer for a particular target cell. The structure of our selected
chimera suggests that post-entry viral processing is critical. The
implication is that efforts to develop modiﬁed AAV capsids speciﬁcally
adapted not only for cellular entry but also for post-entry processing
in particular cell types and under certain conditions of infection are
likely to produce more useful vectors for gene transfer.
Materials and methods
Production of chimeric viral library
To make chimeric Cap genes we beganwith plasmids: pXR1, pXX2,
pXX10, pACG4, pXR5, pAAV7, pAAV8, pAAV9 that contain the Cap
genes for AAV1, 2, 3, 4, 5, 7, 8, and 9 respectively. Cap sequences were
excised by digestionwith Swa I–Not I; SwaI–XbaI; Swa I–Nco I; Swa I–
Not I; Eco RI–Not I; Swa I–Eco RI; Swa I–Eco RI; Swa I–Eco RI;
respectively. Sequences were gel recovered and then chimeric
sequences were created by doing shufﬂing and staggered extension
process (STEP) reactions as described previously (Stemmer, 1994a,
1994b; Crameri et al., 1998; Zhao et al., 1998) (Fig. 1A). For shufﬂing,
DNA was fragmented by DNAse and in some cases digestion with
restriction enzymes Hae III, Nla IV, Mnl I, Hpa II, Bsa JI, Hpy 188 III.
The PCR reactions using pfu Polymerase were performed both on
mixtures of all serotypes and subsets of the serotypes. Numerous
different annealing temperatures and elongation times were
employed for both the shufﬂing and the STEP reactions. The
ampliﬁcation primer from the left end of Cap was principally: Primer
1, TATGGCTGCCGATGGTT (encompassing the ATG start site). Primer
20, TATGACTGACGGTTAC and primer 21, ATGTCTTTTGTTGATC were
also employed to capture chimera that terminated in AAV4 or AAV5
sequences respectively. For the right end of Cap the primer was
primer 4, GGTTTATTGATTAAC.
For a ﬁnal ampliﬁcation, PCR products were ampliﬁedwith primers
3a: GTTATCTTCCAGATTGG and 2a: CGGTTTATTGATTAA that were
nested with respect to primer 1 and primer 4 and that hybridized to
the corresponding region from all serotypes except AAV5. In addition
we employed primers from the center of the Cap gene to do half-length
ampliﬁcations: primer 5, AACCTTACCAGCACGGT with primer 4 and
primer 6, ACCGTGCTGGTAAGGTT with primer 1. The half-length
products were then mixed, denatured, annealed, and extended with
polymerase. All synthesized Cap genes were pooled.
We cloned the resultant library of chimeric Cap genes into pAV2 to
replace the AAV2 Cap gene. (pAV2 contains the entire sequence of
AAV2 inserted into a pBR vector (Laughlin et al., 1983).) We
constructed amodiﬁed cloning plasmid as follows: pAV2was digested
with Xho I and Sna BI to remove almost all Cap sequences. A linkerwas
inserted that replaced all the bases deleted from the 3′ end of AAV
between the Sna BI site and primer 2a and that also inserted a unique
Avr II site to create plasmid pAVCP1. The linker wasmade by annealing
TCGAGGCGGCCGCCCTAGGTCTCTGCGTATTTCTTTCTTATCTAGTTTC-
CATGGCTAC to GTAGCCATGGAAACTAGATAAGAAAGAAATACGCAGA-
GACCTAGGGCGGCCGCC. The cloning vector was derived by digesting
pAVCP1 with Swa I and Avr II, gel recovering the major band, and
ligating a set of linkers to both the SwaI site and the Avr II sites. The
linker for the Swa I site was made by annealing AAATCAGGTATGG-
CTGCCGATG to TTTAGTCCATACCGACGGCTACCAATAGAAGGTCTAACC;
the linker for the AVR II site was made by annealing CTAGTTCAACT-
GAAACGAATTAAA to TTAATCAATAAACCGTTTAATTCGTTTCAGTTGAA.
These linkers created extensive overhangs each of whichwas precisely
complementary to the ﬁnal PCR ampliﬁcation primer from the
respective ends of the synthesized Cap genes (primers 3a and 2a).
This fragment with ligated linkers was gel recovered.
The libraries of PCR fragments that had been ampliﬁed by
primers 3a and 2a were then subjected to partial digestion of the 3′
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chimeric fragments and the linker modiﬁed pAVCP1 fragments were
annealed and ligated. Since the T4 polymerase activity will degrade
each 3′ end past the end of the overhang the resultant plasmids can
only ligate on one strand and will contain 2 single-stranded regions.
These annealing/ligation products were used to transform XL-10
Gold cells.
To produce the viral library 293T cells in 10 cm plates at 50%
conﬂuence were transfected by the CaCl2 method. Plates received
3.0 μg of pDG (Grimm et al., 1998) or adenovirus at an MOI of 5
and varying amounts of library plasmids. Plates were incubated
2 days. Harvesting was by scraping cells. Cells were centrifuged,
resuspended in PBS, divided into 2 equal aliquots, and then pelleted
at 5000 rpm for 5 min. Supernatant was removed and pellets were
stored at −20 °C until processing. To determine the amount of
virus produced (genome containing particles) we employed a
procedure developed previously (Ward, Clement, and Linden,
2007).
The frozen pellet was resuspended in 100 μl TE then frozen and
thawed 3×. 5.0 μl 3.0 M NaCl, 2.0 μl 100 mMMgCl2, and 1.0 μl 500 mM
tris (8.0) were added. This was followed by the addition of 1.0 μl
benzonase (5 U/μl) and 0.5 μl DNAse (10 U/μl). Incubation was at
37 °C for 2 h. Then 5 μl prot. K (10 mg/ml), 5 μl 10% SDS, and 10 μl
250 mM EDTA were added. Incubation was at 37 ° for a further 2 h. or
until the solution was clear and there was no precipitate. 10.0 μl
samples were processed by adding 1.5 μl of 1.5 N NaOH and incubating
at 37 °C for 30 min then analyzed by gel electrophoresis. Electro-
phoretic separation was on 0.8% agarose gels with Tris–borate–EDTA
buffer. Gels were dried, rehydrated, stainedwith SYBRGreen, and then
photographed.
Chimeric virion selection
Hep G2 or Hep 3B cells at 70% conﬂuence were infected with the
viral library at several dilutions. 4 h post-infection media was
removed, cells were washed once with PBS, and media was replaced.
Cells were infected with adenovirus 2 at an MOI of 5. Cells were
harvested at 48–72 h depending upon CPE. One fraction was
processed for gel electrophoresis for the purpose of quantitation. A
separate fraction was used to repeat the above infection. At each
passage virus from the lowest dilution that gave a detectable signal
was used for the next infection. Adenovirus was heat inactivated
between each passage.
After 3 cycles of selection viral capsids were disrupted by NaOH or
boiling and the viral Cap genes were ampliﬁed by PCR. PCR primers
were CCGATATCGATATGGCTGCCGATGGTT and ACCTCTAGAC-
CAAAGTTCAACTGA that contain a Cla I and Hd III site respectively.
The PCR products were digested with Cla I and Hd III followed by
ligation into Hd III–Cla I digested pBlueScript. Ligation products were
used to transform XL-10 Gold cells. Individual clones were ampliﬁed
and sequenced. Cap sequences of selected clones were ampliﬁed
from the pBluescript vector using the same primers (2a and 3a) used
to make the library. With T4 digestion they were inserted into
pAVCP1. The product of this ligation was ampliﬁed and digested with
Sna BIHd III. The product of this digestion was ligated into Pme IHd III
digested pAAV8 to form the packaging construct for the chosen
chimera.
Recombinant AAV generation
Recombinant virus was made by standard method of CaCl2 triple
transfection of equimolar amounts of pTRUF11 (contains GFP), pXX6,
and either pXR1, pXX2, pXX10, pACG4, pXR5, pAAV6, pAAV7, pAAV8,
pAAV9, or p.2A into non-conﬂuent 293T cells. To harvest; cells were
scraped, centrifuged, resuspended in TE, frozen and thawed 3×, and
benzonase digested. The product was stored at −80 °C.Testing chimeric virions on cell lines
Cultures of Hep G2, Hep3B, and HEK 293T cells in 6-well plates at
50–70% conﬂuence or 100% conﬂuence were infected at 4 e3 per cell.
After 2 or more days plates were photographed then harvested for
ﬂow cytometry on a Beckton Dickson FACSCanto ﬂow cytometer using
FACS Diva software.
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